Disease · MONDO_0000594

pervasive developmental disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pervasive developmental disorder. Diseases, record MONDO_0000594. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000594

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pervasive developmental disorder; Open Targets
Open Targets ID: MONDO_0000594; Open Targets
Disease Ontology: DOID:0060040; Disease Ontology
MeSH: D002659; MeSH
NCI Thesaurus: C97179; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 3 of its 5 drugs, from ClinicalTrials.gov; Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RISPERIDONE	CHEMBL85	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ARIPIPRAZOLE	CHEMBL1112	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MIRTAZAPINE	CHEMBL654	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CX516	CHEMBL136800	Small molecule	Phase 2/3	TTD	1	0	0	Drugs and targets
ZIPRASIDONE	CHEMBL708	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets7

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HTR2A	5-hydroxytryptamine receptor 2A	4	Serotonin 2a (5-HT2a) receptor antagonist	Phase 3	https://conductscience.org/library/genes/3356	Drugs and targets
DRD2	D(2) dopamine receptor	3	Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist	Phase 3	https://conductscience.org/library/genes/1813	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	3	Serotonin 2c (5-HT2c) receptor antagonist	Phase 3	https://conductscience.org/library/genes/3358	Drugs and targets
ADRA2A	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 antagonist	Phase 3	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 antagonist	Phase 3	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 antagonist	Phase 3	https://conductscience.org/library/genes/152	Drugs and targets
HTR1A	5-hydroxytryptamine receptor 1A	1	Serotonin 1a (5-HT1a) receptor partial agonist	Phase 3	https://conductscience.org/library/genes/3350	Drugs and targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00870727	Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders	Phase 3	33	2018-11-28	Pervasive Developmental Disorder	ARIPIPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01302964	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders	Phase 3	30	2018-11-07	Autism Spectrum Disorders	MIRTAZAPINE	Its record names the disease	ClinicalTrials.gov
NCT00166595	Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)	Phase 1/2	100		Child Development Disorders, Pervasive	RISPERIDONE	Its record names the disease	ClinicalTrials.gov
NCT00261508	A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD)	Phase 3	80		DCild Development Disorders, Pervasive, Autistic Disorder, Developmental Disabilities, Asperger Syndrome, Rett Syndrome	RISPERIDONE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00208559	Ziprasidone in Children With Autism: A Pilot Study	Phase 2	15		Autism	ZIPRASIDONE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm 1. Aripiprazole Oral Product vs Arm 2. Placebo Oral Capsule: deaths from any cause	0 of 17	0 of 16	33	NCT00870727	Trial comparisons
Arm 1. Aripiprazole Oral Product vs Arm 2. Placebo Oral Capsule: serious adverse events	0 of 17	0 of 16	33	NCT00870727	Trial comparisons
Arm 1. Aripiprazole Oral Product vs Arm 2. Placebo Oral Capsule: Number of Participants Improved as Measured by the Clinical Global Impression-Global Improvement Scale (Improvement Defined as CGI-I=1 or CGI-I=2)	11 of 16	3 of 15	31	NCT00870727	Trial comparisons
Mirtazapine vs Placebo: deaths from any cause	0 of 20	0 of 10	30	NCT01302964	Trial comparisons
Mirtazapine vs Placebo: serious adverse events	0 of 20	0 of 10	30	NCT01302964	Trial comparisons

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
15492353	RESULT	1	PubMed
35241779	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000594

GET https://conductscience.org/api/diseases/v1/MONDO_0000594/drugs

API reference For AI assistants